Hims & Hers Health Inc. HIMS stock is trading lower on Tuesday. The U.S. Food and Drug Administration (FDA) issued a warning letter to Hims & Hers Health, dated Sept. 9, addressed to the company’s CEO, Andrew Dudum.HIMS is encountering selling pressure. See the trading setup here.The FDA flagged misleading claims made by Hims & Hers Health regarding its compounded semaglutide products. Semaglutide is an active ingredient in Novo Nordisk A/S’ NVO flagship Wegovy and Ozempic.In a warning letter, the FDA said ...